etrozole therapy in men with moderate to severe oligoasthenozoospermia.
Phase 4
- Conditions
- Health Condition 1: N468- Other male infertility
- Registration Number
- CTRI/2021/08/035725
- Lead Sponsor
- JIPMER INTRAMURA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subfertile men with moderate to severe oligoas-thenozoospermia attending male infertility clinic, WCH, JIPMER during the study period.
Exclusion Criteria
1. Ejaculatory duct obstruction or surgery for male factor infertility
2. History of mumps orchitis, chronic tobacco and alcohol abuse.
3. Ongoing medical treatment including gonadotro-pins, anabolic steroids, and cancer chemotherapy
4. Leukocytospermia (more than 1 million/ml).
5. Severe varicocele and previously diagnosed Kli-nefelter syndrome.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the efficacy of letrozole in improving semen parameters with placebo treatment in patients with moderate to severe oligoasthenozoospermia.Timepoint: After 3 months of letrozole therapy
- Secondary Outcome Measures
Name Time Method 1. To monitor the side effects of letrozole. <br/ ><br>Timepoint: monitoring will be done every month via teleconsultation(4weeks, 8weeks,12weeks) <br/ ><br>patient can immediately report if any adverse drug reactions occur. <br/ ><br>;2. To measure the alterations in serum oestradiol and testosterone produced by letrozole. <br/ ><br>Timepoint: After 3 months of letrozole therapy